Marker Therapeutics to Present at the 2024 Ladenburg Thalmann & Co. Virtual Oncology Innovators and Investors Symposium
Marker Therapeutics, Inc. (MRKR)
Last marker therapeutics, inc. earnings: 11/12 04:01 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
HOUSTON, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that Juan Vera, M.D., President and Chief Executive Officer of Marker Therapeutics, will present at the Ladenburg Thalmann & Co. Virtual Oncology Innovators & Investors Symposium. This virtual investor event will be held on December 12, 2024. Dr. Vera will present an overview of Marker’s technology and clinical developments on Thursday, December 12, 2024, at 1:30 PM EST. Details of the presentation are as follows: Event:2024 Ladenburg Thalmann & Co. Virtual Oncology Innovators & Investors SymposiumDate: December 12, 2024, at 1:30 PM ESTLocation:Virtual Event Registered participants will have access to the presentation through the event portal on the day of the event. After the event, Dr. Vera’s p
Show less
Read more
Impact Snapshot
Event Time:
MRKR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRKR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRKR alerts
High impacting Marker Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
MRKR
News
- Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma [Yahoo! Finance]Yahoo! Finance
- Marker Therapeutics Announces $16.1 Million Private Placement [Yahoo! Finance]Yahoo! Finance
- Marker Therapeutics Announces $16.1 Million Private PlacementGlobeNewswire
- Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with LymphomaGlobeNewswire
- Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer [Yahoo! Finance]Yahoo! Finance
MRKR
Analyst Actions
- 10/21/24 - Ladenburg Thalmann
MRKR
Sec Filings
- 12/26/24 - Form 4
- 12/23/24 - Form 4
- 12/23/24 - Form 8-K
- MRKR's page on the SEC website